Phio Pharmaceuticals Corp (PHIO) Stock Price & News - Google Finance

Finance

HomePHIO • NASDAQ

Phio Pharmaceuticals Corp

$1.03

Pre-market:

$1.01

(1.94%)-0.020

Closed: Dec 24, 8:52:39 AM GMT-5 · USD · NASDAQ · Disclaimer

Previous close

$1.03

Year range

$0.97 - $9.79

Market cap

11.09M USD

Avg Volume

433.64K

P/E ratio

-

Dividend yield

-

Primary exchange

NASDAQ

Market news

Economy grows, chip tariff delay, new S&P 500 record and more in Morning Squawk

Investor's Business Daily

Stock Market Today: Dow Wavers After Surprise Jobless Claims; Nvidia Retakes Key Level (Live Coverage)

Investing News Network

NYSE Content Advisory: Pre-Market Update + S&P 500 Powers to Record Close Above 6,900

One of the most important ‘Magnificent Seven’ members is rumbling to life. Here’s what that means for tech and the S&P 500.

S&P 500 record, commodities, Apple CEO buys Nike shares: 3 Things

Industrials power ahead in 2025 as S&P 500’s third-best performing sector

About

Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia

Founded

2011

Website

Employees

5

Search

Clear search

Close search

Google apps

Main menu